Promis Neurosciences (PMN)
(Delayed Data from NSDQ)
$1.60 USD
-0.42 (-20.70%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $1.53 -0.07 (-4.38%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Income Statements
Fiscal Year end for Promis Neurosciences falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 14 | 23 | 8 | 4 | 6 |
Income After Depreciation & Amortization | -14 | -23 | -8 | -4 | -6 |
Non-Operating Income | 1 | 6 | -1 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -13 | -18 | -9 | -4 | -6 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -13 | -18 | -9 | -4 | -6 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -13 | -18 | -9 | -4 | -6 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -14 | -23 | -8 | -4 | -6 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -14 | -23 | -8 | -4 | -6 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 12.29 | 7.50 | 5.80 | 4.77 | 4.34 |
Diluted EPS Before Non-Recurring Items | -1.07 | -2.41 | 0.00 | -0.60 | -1.20 |
Diluted Net EPS (GAAP) | -1.07 | -2.41 | -1.43 | -0.89 | -1.35 |
Fiscal Year end for Promis Neurosciences falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 3.67 | 3.88 | 2.52 | 2.90 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -3.67 | -3.88 | -2.52 | -2.90 |
Non-Operating Income | NA | 0.12 | 0.37 | 0.23 | 0.64 |
Interest Expense | NA | 0.08 | 0.08 | 0.08 | 0.05 |
Pretax Income | NA | -3.64 | -3.58 | -2.36 | -2.31 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -3.64 | -3.58 | -2.36 | -2.31 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -3.64 | -3.58 | -2.36 | -2.31 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 19.53 | 12.29 | 12.37 | 8.58 |
Diluted EPS Before Non-Recurring Items | NA | -0.19 | -0.09 | -0.19 | -0.27 |
Diluted Net EPS (GAAP) | NA | -0.19 | -0.03 | -0.19 | -0.27 |